<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95823">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974856</url>
  </required_header>
  <id_info>
    <org_study_id>PTL-00172</org_study_id>
    <nct_id>NCT01974856</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies, Inc. Prosigna™ Gene Signature Assay</brief_title>
  <official_title>A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies, Inc. Breast Cancer Intrinsic Subtype Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoString Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoString Technologies, Inc.</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the extent to which the Prosigna™ Breast
      Cancer Prognostic Gene Signature Assay affects the medical oncologist's treatment
      recommendations regarding adjuvant chemotherapy and actual treatments received for patients
      with early-stage breast cancer. Changes in treatment recommendations will include (1)
      hormonal therapy alone, (2) hormonal therapy plus chemotherapy, and (3) changes in types of
      chemotherapy if chemotherapy was recommended before and after the test
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The proportion of patients whose choice of treatment is changed as a result of receiving the Prosigna test result.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Postmenopausal women with node-negative, estrogen-receptor positive, HER2-negative
        early-stage breast cancer. Investigators will offer enrollment to consecutively seen women
        who meet the entry criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resected node-negative, estrogen-receptor-positive, HER2-negative early- stage
             invasive breast cancer (T1-T2, N0, pN0 (i+), pN0 (mol+), M0)

               -  Estrogen receptor status will be evaluated by Immunohistochemistry (IHC) and
                  more than 1% of stained tumor cells will be considered positive.

               -  HER2 status will be evaluated by IHC (0 or 1+, or 2+ will be considered
                  negative) and by in-situ fluorescence hybridization.

          -  Postmenopausal women defined as:

               -  Natural Amenorrhea &gt; 12 months, regardless of age

               -  Bilateral oophorectomy, regardless of age (the oophorectomy must have been
                  carried out at least 4 weeks before entering the study)

               -  Radiological castration with amenorrhea &gt; 3 months, regardless of age

               -  Hysterectomy and postmenopausal blood levels

          -  Able to give consent

          -  Eligible for treatment of breast cancer with adjuvant chemotherapy

          -  ECOG performance status of 0 or 1

        Exclusion Criteria:

          -  Tumor size T3-T4

          -  Non-invasive breast cancer (e.g., Paget's disease, DCIS)

          -  Tumors with nodes that are not N0, pN0 (i+), or pN0 (mol+)

          -  Tumors that are estrogen-receptor negative or HER2 positive

          -  Have metastatic disease

          -  Unable to give informed consent

          -  Unable to complete patient reported outcome surveys

          -  Have contraindications for adjuvant chemotherapy

               -  Age, performance status, significant comorbidities

          -  ECOG performance status &gt; 1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia Harbeck, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leitung des Brustzentrums der Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PD Dr. Christian Schem</last_name>
      <phone>0049 431 597-0</phone>
    </contact>
    <investigator>
      <last_name>PD Dr. Christian Schem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof Wolfgang Janni</last_name>
      <phone>0731 / 500-58501</phone>
    </contact>
    <investigator>
      <last_name>Prof Wolfgang Janni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 28, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
